NASDAQ: MRTX       Mirati Therapeutics
Last Price Today's Change   Day's Range   Trading Volume
78.18   +1.88 (2.46%)  74.01 - 79.77  181,977


Avg Volume (4 weeks):590,310
4 Weeks Range:66.01 - 96.93
4 Weeks Price Volatility (%):
52 Weeks Range:55.11 - 132.59
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Mirati Therapeutics is an American biotechnology company. The company’s medical focus is precision medicine: genetically targeted oncology therapeutics for selected patients. Mirati’s drug candidates target specific genetic and epigenetic drivers of cancer. Its portfolio includes MGCD265, MGCD516, and mocetinostat. MGCD265 and MGCD516 are orally bioavailable inhibitors with distinct target profiles aiming to treat patients with non-small cell lung cancer and other solid tumors. MGCD265 and MGCD516 are in clinical development. Mocetinostat is an orally bioavailable, Class 1 selective histone deacetylase inhibitor in clinical development in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

3244  2605  268  2905 

Top 10 Active Counters
 TOPS 0.464+0.229 
 CELG 108.24+0.11 
 ACHN 6.760.00 
 TBLT 0.188+0.035 
 AVP 5.60-0.05 
 SQQQ 19.31-2.04 
 F 5.015-0.175 
 CHK 0.157-0.013 
 SPCB 1.19+0.70 
 GE 7.905+0.285 
Partners & Brokers